TSOI Overzicht aandelen Therapeutic Solutions International, Inc. Meer informatie
Risicoanalyse + 2 meer risico's
Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Therapeutic Solutions International, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Therapeutic Solutions International Historische aandelenkoersen Huidige aandelenkoers US$0.0002 52 Week Hoogtepunt US$0.0017 52 Week Laag US$0.0002 Bèta 1.51 1 maand verandering -50.00% 3 maanden verandering -69.23% 1 Jaar Verandering -86.67% 3 jaar verandering -99.19% 5 jaar verandering -91.67% Verandering sinds IPO -99.86%
Recent nieuws en updates Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 15
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients Mar 05
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene Oct 21 Meer updates bekijken Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 15
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients Mar 05
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene Oct 21
Res Nova Bio Appoints George Delgado to Scientific Advisory Board Oct 18
Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils Oct 01
Therapeutic Solutions International Appoints Navneet Boddu to Scientific Advisory Board Sep 19
Therapeutic Solutions International, Inc. Announces FlorStilbene™? Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer Aug 22 Allogen Biologics Inc. Successfully Manufactures JadiCell
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™ Jul 21
Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 16
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease Nov 15
Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient Oct 25
Therapeutic Solutions International Identifies Cd103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for Jadicell Mesenchymal Stem Cell Mediated Lung Protection Oct 06 Therapeutic Solutions International, Inc. announced that it expects to receive $10 million in funding from GHS Investments, LLC Sep 21
Therapeutic Solutions International Announces Positive Data and Filing of Patent Covering the Use of Campbellcell for Treatment of Bipolar Disorder by the Company’S Suicide Prevention Based Spin-Off Campbell Neurosciences Sep 20
Therapeutic Solutions International Develops Post Jadicell Maintenance Therapy for Chronic Obstructive Pulmonary Disease Sep 13
Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome Aug 30
Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome Aug 26
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16
Therapeutic Solutions International, Inc. Reports Superior Efficacy of ApoptoCyte™ on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches Aug 13
Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells Jul 29
Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial Jul 19
Therapeutic Solutions International Appoints Donald Banerji to Scientific Advisory Board May 26
Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial May 24 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International Announces New Data Demonstrating Enhancement of Therapeutic Activities of the Jadicell May 13 Therapeutic Solutions International, Inc. Files Investigational New Drug Application May 10
Therapeutic Solutions International, Inc. Announces Launching of Phase III Clinical Trial for Treating Covid-19 Lung Damage Using its Jadicell Universal Donor Stem Cell Drug May 03
Therapeutic Solutions International Identifies Novel Biological Pathway Apr 20
Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model Feb 08
Therapeutic Solutions International Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation Jan 04
Therapeutic Solutions International Successfully Treats No Option Patients with its JadiCell Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial Dec 31
Therapeutic Solutions International, Inc. Receives Patent for Cancer and COVID-19 Treatment Dec 29
Therapeutic Solutions International, Inc. Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in Covid-19 Model Sep 24
Therapeutic Solutions International Successfully Treats Veteran Navy Seal Suffering from Chronic Traumatic Encephalopathy with Jadicell™ Adult Stem Cells Under Right to Try Law Sep 14
Therapeutic Solutions International, Inc. Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer Aug 31
Therapeutic Solutions International, Inc. Announces Positive Preclinical Results Using Jadicells™ in Animal Model of Chronic Obstructive Pulmonary Failure (COPD) Aug 24
Therapeutic Solutions International, Inc. Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Aug 12
Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell™ Chronic Traumatic Encephalopathy (CTE) Clinical Trial Aug 10
Therapeutic Solutions International, Inc. Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell™ Universal Donor COVID-19 Therapy Aug 06
Therapeutic Solutions International, Inc. Spin-Off Campbell Neurosciences Initiates Pilot Implementation of Campbell Score™ with California Concierge Medical & Wellness Inc Jul 03
Therapeutic Solutions International Demonstrates Potent Brain Protective Activity of JadiCells in Animal Model of Post-Covid-19 Neurological Damage Jul 01
Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models Using Low Dose Naltrexone and T Regulatory Cell Stimulation Jun 17
Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC Jun 08
Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model Jun 03
Therapeutic Solutions International, Inc. Announces New Data Demonstrating Synergy Between its Tumor Blood Vessel Killing Vaccine, StemVacs-V iPSC and Specific Immunological Adjuvants May 25
Therapeutic Solutions International, Inc. Develops Novel Stem Cell Based Therapy to Reduce Lung Scarring: Potential Solution to Post COVID-19 Lung Deterioration May 22
Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model May 18
Therapeutic Solutions International, Inc. Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy Apr 27
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Announces Novel Cancer-Resistant iPSC-Derived Dendritic Cell Immunotherapy: StemVacs-V™ Mar 17
Therapeutic Solutions International, Inc. Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention Mar 05
Therapeutic Solutions International Approves on RangeMe to sell QuadraMune™ and NanoStilbene™ Along with Other Supplements Mar 04
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™ Feb 26
Therapeutic Solutions International Uses Stemvacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells Feb 23
Therapeutic Solutions International Appoints Dr. Boris Minev to Scientific Advisory Board Feb 18
Therapeutic Solutions International Reports Preliminary Data Suggesting StemVacs Induces Natural Killer Memory to Cancer Feb 09
Therapeutic Solutions International Enters into Master Sales Agreement with Community Shield LLC Feb 05
Therapeutic Solutions International, Inc. Announces Filing of Patent Disclosing Enhancement of Natural Killer Cell and T Cell Activity by Stemvacs After Treatment with Homotaurine, A Safe Blood-Brain Barrier Permeable Gaba A-R-Specific Agonist Jan 28
Therapeutic Solutions International Reports Regression of Glioma, Lung Cancer and Colorectal Cancer using StemVacs in Animal Models Jan 26
Therapeutic Solutions International Reports Successful Treatment of Breast Cancer Using StemVacs Cellular Immunotherapy Jan 20
Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences Jan 14
Therapeutic Solutions International Reports QuadraMune Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity Jan 06
Therapeutic Solutions International, Inc. Reports QuadraMune Increases T Cell Immunity in Animal Studies Dec 31
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell Dec 19 Therapeutic Solutions International Announces Clinical Trial Assessing "Kaihani Score" Proprietary Biomarker Based Assay for Quantifying Gambling Addiction Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 18
Therapeutic Solutions International, Inc. Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbene Nutraceutical Product Nov 11
Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score Oct 30
Therapeutics Solution International, Inc. Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene Oct 20
Therapeutic Solutions International Appoints Serena Robella as Director of Sales Oct 13 Rendement voor aandeelhouders TSOI US Pharmaceuticals US Markt 7D -33.3% 0.4% -2.1% 1Y -86.7% 2.2% 21.3%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: TSOI presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 2.2 % opleverde.
Rendement versus markt: TSOI presteerde slechter dan US Market , dat het afgelopen jaar een rendement van 21.3 % opleverde.
Prijsvolatiliteit Is TSOI's price volatile compared to industry and market? TSOI volatility TSOI Average Weekly Movement 37.2% Pharmaceuticals Industry Average Movement 11.0% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Stabiele aandelenkoers: De aandelenkoers van TSOI is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van TSOI is het afgelopen jaar gestegen van 28% naar 37%.
Over het bedrijf Therapeutic Solutions International, Inc. richt zich op immuunmodulatie voor de behandeling van verschillende specifieke ziekten in de Verenigde Staten. Het bedrijf ontwikkelt een reeks immuunmodulerende middelen voor kanker, schizofrenie, zelfmoordgedachten en traumatisch hersenletsel, maar ook voor de dagelijkse gezondheid. De paradepaardjes van het bedrijf zijn QuadraMune, een gepatenteerd synergetisch mengsel van pterostilbeen, sulforafaan, epigallocatechingallaat en thymoquionon om de activiteit van natuurlijke killercellen en de productie van gezonde cytokinen te verhogen.
Meer tonen Therapeutic Solutions International, Inc. Samenvatting Hoe verhouden de winst en inkomsten van Therapeutic Solutions International zich tot de beurswaarde? TSOI fundamentele statistieken Marktkapitalisatie US$1.54m Inkomsten(TTM ) -US$2.41m Inkomsten(TTM ) US$85.32k
12.0x P/S-verhouding
-0.4x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) TSOI resultatenrekening (TTM ) Inkomsten US$85.32k Kosten van inkomsten US$29.18k Brutowinst US$56.14k Overige uitgaven US$2.47m Inkomsten -US$2.41m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.00047 Brutomarge 65.80% Nettowinstmarge -2,824.94% Schuld/Eigen Vermogen Verhouding 49.0%
Hoe presteerde TSOI op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/10 07:39 Aandelenkoers aan het einde van de dag 2025/01/10 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Therapeutic Solutions International, Inc. wordt gevolgd door 0 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
